Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2005
11/23/2005CN1701073A Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
11/23/2005CN1701061A New compounds for the inhibition of rotamases and use thereof
11/23/2005CN1701059A Chemotherapeutic agents
11/23/2005CN1700923A Multi-substituted selective androgen receptor modulators and methods of use thereof
11/23/2005CN1700922A 3, 10, and 12a substituted tetracycline compounds
11/23/2005CN1700917A Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
11/23/2005CN1700916A Use of HIV-protease inhibitors to block cell migration and/or invasion, tissue inflitration and oedema formation
11/23/2005CN1699350A Processes and intermediates for preparing anti-cancer compounds
11/23/2005CN1698602A Usage of pyrazoline derivant in the drug preparation for preventing and/or treating cell breeding disease
11/23/2005CN1228449C Ganoderma mycellium antitumour water soluble neteropolysaccharide and its preparation method and use
11/23/2005CN1228343C Substance having steroid-like structure, process for production thereof and antitumor agents containing same
11/23/2005CN1228341C Process for producing camptothecin
11/23/2005CN1228334C Anti-tumour effective constituent cherimoya essence preparation method
11/23/2005CN1228088C Cross-breed vaccine carrier and its application
11/23/2005CN1228057C Compound of solanesol and its preparing process
11/22/2005US6967214 Inhibitors of IMPDH enzyme
11/22/2005US6967210 Multiple sclerosis, brain disorders, analgesics
11/22/2005US6967203 Use of pyridoindolone derivatives for preparing anticancer medicines
11/22/2005US6967198 Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy
11/22/2005US6967197 Also used in production of tumor necrosis factor alpha
11/22/2005US6967100 Propagating islet of langerhans cells; obtain cells, culture in presence of bone morphogenic protein or modulator, monitor proliferation of cells
11/22/2005US6967097 Nucleotide sequences coding enzymatic polypeptide for use in the treatment of viral diseases
11/22/2005US6967094 Peptide for use in treatment of cancer, parkinson's and metabolic disorders
11/22/2005US6967023 solidifying agent consists of a long chain fatty alcohol having at least 15 carbon atoms in its backbone and a fatty acid having at least 18 carbons in its backbone; carrier is semi-solid at rest and liquefies upon application of shear forces
11/22/2005US6967022 Ganglioside-KLH conjugate vaccines plus QS-21
11/22/2005CA2277100C Cyclic sulfone derivatives
11/20/2005CA2467894A1 A composition for prevention and treatment of colon adenomas
11/17/2005WO2005108584A1 Recombinant chemokine-antigen vaccine
11/17/2005WO2005108575A1 T-type calcium channel splice variant compositions and methods
11/17/2005WO2005108420A1 Cancer associated antigens
11/17/2005WO2005108400A1 Pyridoquinazoline derivatives having heterobicyclic substituents
11/17/2005WO2005108399A1 Imidazopyridine compound
11/17/2005WO2005108398A1 6-substituted pyridoindolone derivatives production and therapeutic use thereof
11/17/2005WO2005108355A2 Dihydrobenzothiophenes
11/17/2005WO2005107799A1 REMEDY FOR CANCER CONTAINING ANTI-Necl-5 ANTIBODY AS THE ACTIVE INGREDIENT
11/17/2005WO2005107771A2 Composition comprising a survivin oligonucleotide and gemcitabine for the treatment of cancer
11/17/2005WO2005107748A2 Method of tonic treatment with oxyphenbutazone derivatives
11/17/2005WO2005107731A1 Remedies containing vitamin k2 as the active ingredient
11/17/2005WO2005065266A8 Di-substituted pyrrolotriazine compounds
11/17/2005WO2004108945A3 Oligonucleotide modulation of cell adhesion
11/17/2005WO2004078140A3 SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
11/17/2005WO2003068941A3 Modulation of immune response by non-peptide binding stress response polypeptides
11/17/2005WO2001065911A9 Improved poloxamer and poloxamine compositions for nucleic acid delivery
11/17/2005US20050256315 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
11/17/2005US20050256311 Pyrimidine compounds
11/17/2005US20050256308 Spiro compounds, medicinal compositions containing the same and intermediates of the compounds
11/17/2005US20050256302 Novel peptides having camp producing activity
11/17/2005US20050256209 Psoraleae fructus extracts; administered through topical application, injection, oral administration, or time release dosage form; treating postmenopausal estrogen-deficient osteoporosis without increasing the probability of the subject woman in gaining breast cancer
11/17/2005US20050256208 Pharmaceutical composition containing bakuchiol for treating woman breast cancer
11/17/2005US20050256191 Nitroaniline-based alkylating agents and their use as prodrugs
11/17/2005US20050256180 drugs such as 1 -[4-(aminosulfonyl)phenyl]-8-{[(trifluoromethyl)sulfonyl]amino}-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide, used as antiinflammatory agents, antiarthritic agents, antipyretics or analgesics
11/17/2005US20050256167 Preparation and use of imidazole derivatives for treatment of obesity
11/17/2005US20050256166 Nitrogen-containing compounds
11/17/2005US20050256160 Beta-alanine derivatives and the use thereof
11/17/2005US20050256148 Topoisomerase I inhibitors; improved stability, water solubility, toxicity; anticancer agents; camptothecins bearing an oxime group in position 7; 7-tert-butoxyiminomethyl-20-O-(4-trimethyl-ammonium-3-hydroxy)butanoyl-camptothecin bromide; parasitic or viral infections
11/17/2005US20050256143 Purine nucleosides
11/17/2005US20050256142 New purine derivatives
11/17/2005US20050256140 Condensed pyridines and pyrimidines with tie2 (tek) activity
11/17/2005US20050256122 Substituted pyridazinones
11/17/2005US20050256110 Cyanopyrroles
11/17/2005US20050256079 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
11/17/2005US20050256066 Fredericamycin derivatives
11/17/2005US20050256060 Mono-and disaccharide derivatives
11/17/2005US20050256051 Nuclear receptor-mediated introduction of a PNA into cell nuclei
11/17/2005US20050256049 Chimeric toxins for targeted therapy
11/17/2005US20050256048 Selective androgen receptor modulators and methods for their identification, design and use
11/17/2005US20050256034 Dioxolane analogs for improved inter-cellular delivery
11/17/2005US20050255573 An in vitro method of maintaining a mouse or human pluripotent cell in a pluripotent state by increasing expression of a gene that encodes a factor which acts intracellularly and maintainspluripotency, where the factor is a polypeptide of the sequence of SEQ ID NO: 4; cultures
11/17/2005US20050255549 IRAK-4: compositions and methods of use
11/17/2005US20050255529 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
11/17/2005US20050255454 Administering antigens capable of causing specific immune reaction(s) directed against an infectious agent and/or cells infected with the infectious agent, and decreasing a different specific immune reaction direct towards the infectious agent, infected cells and/or uninfected cells; immunotherapy
11/17/2005US20050255443 Method of screening cell growth inhibitor and cell growth inhibitor
11/17/2005US20050255116 Combination of tumor-associated surface protein antigens and tumor-associated sugars in the treatment and diagnosis of cancer
11/17/2005US20050255110 Method for ex vivo immunization using heterologous intact bispecific and/or trispecific antibodies
11/17/2005US20050255103 Remedy for lung cancer
11/17/2005US20050255102 binds to alpha v beta 6 and not other alpha v integrins or non-specific integrins; inhibits the binding of alpha v beta 6 to latency associated peptide with an IC50 value lower than that of 10D5 and binds alpha v beta 6 in manner that does not distinguish between the use of Ca2+/Mg2+ and Mn2+ for cation
11/17/2005US20050255088 Administering mutant Salmonella sp. for therapy of solid tumor cancer, disrupted msbB gene and is capable of targeting a solid tumor cancer
11/17/2005US20050255085 Prevention of recurrence and metastasis of cancer
11/17/2005US20050255041 Administering monoclonal antibody or antigen binding fragment accession number 270404-01; primary and metastatic tumors
11/17/2005DE10392697T5 Herstellung und Standardisierung von immunmodulierenden Peptid-verknüpften Glucanen mit nachweisbarer oraler Resorbierbarkeit aus Coriolus Versicolor Preparation and standardization of immunomodulating peptide-linked glucans with detectable oral absorbability from Coriolus Versicolor
11/17/2005CA2821167A1 Drug delivery liposomes containing anionic polyols or anionic sugars
11/17/2005CA2566398A1 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
11/17/2005CA2566228A1 Method of tonic treatment with oxyphenbutazone derivatives
11/17/2005CA2566184A1 Imidazopyridine compound
11/17/2005CA2566080A1 Kit for treatment of cancer
11/17/2005CA2566041A1 T-type calcium channel splice variant compositions and methods
11/17/2005CA2565367A1 Dihydrobenzothiophenes
11/17/2005CA2565218A1 Compounds and compositions for treatment of cancer
11/17/2005CA2565215A1 Method and system to remove soluble tnfr1, tnfr2, and il2 in patients
11/17/2005CA2562750A1 Composition comprising a survivin oligonucleotide and gemcitabine for the treatment of cancer
11/17/2005CA2562561A1 6-substituted pyridoindolone derivatives production and therapeutic use thereof
11/17/2005CA2560865A1 Cancer associated antigens
11/16/2005EP1595954A1 Human papilloma virus inhibition by antisense oligonucleotides
11/16/2005EP1595951A1 Diagnosis and treatment of diseases using peptides which are bound by specific anti-anti-t-cell receptor vbeta antibodies
11/16/2005EP1595878A1 Indole derivatives with apoptosis inducing activity
11/16/2005EP1595867A1 Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
11/16/2005EP1595548A2 Anti-neovasculature preparations for treating cancer
11/16/2005EP1595546A1 Remedy for cancer
11/16/2005EP1595543A2 Antineoplastic pharmaceutical compositions comprising taurolidine or taurultam and 5-fluorouracil
11/16/2005EP1595536A1 Pharmaceuticals comprising shikonins as active constituent
1 ... 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 ... 2211